GE Healthcare announced today that it executed a master research agreement with ImaginAb Inc. for the development of new positron emission tomography (PET) diagnostic imaging agents for cardiovascular diseases.
ImaginAb, founded in 2007 by UCLA faculty, is a biotechnology company specialized in diagnostic imaging and applications with a focused pipeline toward cancer and immunology.
The Inglewood, Calif.-based company’s antibody fragment technology will be the focus of research with GE Healthcare. The technology reworks intact antibodies into fragments that are better for imaging without provoking an immune response in patients, allowing for repeating imaging.
The companies will collaborate to develop targeted molecular diagnostics, specifically for high-risk cardiovascular disease. GE officials hope to develop products for their own portfolio as well as to offer to strategic partners, according to the release.
Here’s a roundup of companies announcing new distribution deals and other joint ventures.
- Generex licenses RapidMist to Amarantus for $10 million
Generex Biotechnology Corp. (OTC:GNBT) announced today that it has licensed its RapidMist drug delivery technology to Amarantus BioSciences Inc. for a non-refundable license fee of $10 million.
California-based biotech company Amarantus plans to use RapidMist technology with its proprietary MANF proteins, the most advanced product development for which centers on therapy for Parkinson’s disease, currently funded by the Michael J. Fox Foundation for Parkinson’s Research.
The agreement grants Amarantus an exclusive worldwide license for clinical and regulatory development and commercialization of RapidMist technology in connection with all therapeutic applications developed by Amarantus, outside of diabetes treatment.
The two companies plan on working together to pursue Amarantus technologies for treatment of diabetes.